Selected toxicities of targeted therapies: presentation and management.
Semin Oncol
; 40(4): 499-510, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23972714
ABSTRACT
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Inibidores de Proteínas Quinases
/
Neoplasias Renais
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article